The Transformation of Clinical Laboratories with CLIA Technology: The Contribution of INNOVIQURE NEXUS

Clinical laboratories are of critical importance in the medical field for accurate diagnosis and treatment. Today, the increasing number of patients and complex test demands have highlighted the need for speed, precision, and efficiency in laboratories. At this point, CLIA (Chemiluminescent Immunoassay) technology offers solutions that elevate laboratory performance to the next level. Innovative devices like INNOVIQURE NEXUS maximize the potential of this technology, making a significant impact in the industry.

What is CLIA Technology and Why is It Important?

CLIA technology is used in medical diagnostic tests, particularly for detecting biomarkers at low levels. This technology is based on measuring the light emitted as a result of a chemical reaction and stands out with the following advantages:

  • Sensitivity: The ability to detect even low concentrations of biomarkers.
  • Fast Results: Reliable test outcomes in a short period of time.
  • Versatility: The capacity to analyze various types of biomarkers.

These features enable laboratories to work more effectively and make quicker decisions in patient care.

INNOVIQURE NEXUS: Integration of CLIA Technology

INNOVIQURE NEXUS is one of the most efficient solutions utilizing CLIA technology. This innovative device has numerous features that facilitate laboratory workflows:

  • Compact Design: Weighing less than 38 kg, it is ideal for use in various settings.
  • User-Friendly Interface: Its touchscreen and simple control panel make it easy to operate.
  • High Capacity: Offers 30 sample and 10 reagent positions with 24-hour uninterrupted cooling and storage.
  • Smart Functions: Optimized alarm classification and compatibility with all Shine series analyzers’ reagents and consumables.

Accelerating Transformation in Laboratories

The fast, precise, and efficient performance offered by INNOVIQURE NEXUS redefines workflows in clinical laboratories. Its user-friendly interface allows laboratory staff to operate the device with ease and conduct tests with fewer errors. Additionally, the STAT channel enables much faster analysis of urgent samples.

A Step Towards the Future

The rapid advancement in medical technologies is making laboratory processes more efficient, and innovative devices like INNOVIQURE NEXUS are leading this transformation. Supported by the features of CLIA technology, this device provides a versatile solution for the present and future of laboratories.

Contact us to bring the INNOVIQURE NEXUS advantage to your laboratory: [email protected]

A new age in science: Innovations in Cardiovascular Diagnosis with hs-cTnI Test

A major step forward in the early diagnosis of cardiovascular diseases: The high-sensitivity cardiac troponin I (hs-cTnI) test is revolutionising this field. SHD Test is pioneering this innovation by contributing not only to clinical results but also to academic research.

Clinical Accuracy and Reliability
Troponin I protein is one of the most reliable biomarkers for detecting cardiac muscle damage. SHD Test’s hs-cTnI solution is accurate even at very low levels of 5 pg/ml. This enables early diagnosis as well as rapid detection of even less obvious cases. This high accuracy reduces false negative rates, especially in low-risk patients.

New Approaches in Diagnostic Technology
The devices offered by SHD Test stand out with their high sensitivity as well as their portability and fast result capability. These features are particularly suitable for use in intensive care units, emergency services and mobile health platforms. The widespread use of high-sensitivity testing ensures more consistent clinical results and helps to make faster and more informed decisions in patient management.

Scientific Collaborations and Expanding Opportunities
SHD Test aims to support innovative projects in the academic world. To this end, it offers hs-cTnI tests free of charge for use in research projects. This enables the development of new diagnostic protocols and independent validation of existing approaches. Thus, while contributing to the academic literature, gaps in clinical practice are also filled.

Personalised Medicine and POCT Trends
In the healthcare sector, personalised medicine and portable diagnostic devices (POCT) are becoming increasingly important. hs-cTnI tests epitomise this trend, increasing patient satisfaction and improving the efficiency of healthcare systems. SHD Test’s technology not only meets these demands, but also contributes to the establishment of new diagnostic standards.

Steps for the Future
The hs-cTnI test not only improves current diagnostic methods, but also lays the foundation for future healthcare innovations. We invite the academic and clinical communities to explore and develop these innovations. Please contact us for further information and collaboration opportunities.

Advancing POCT Diagnostics: Transforming Healthcare Through Academic Collaboration

In the rapidly evolving world of healthcare, timely and accurate diagnostics have always been at the forefront of better patient outcomes. One of the latest breakthroughs in this field comes from implementing high-sensitivity cardiac troponin I (hs-cTnI) tests on point-of-care testing (POCT) devices. This innovation promises to revolutionize emergency diagnostics and mobile healthcare, setting a new standard for rapid and reliable patient care.

High-Sensitivity, Rapid Diagnostics: A Game-Changer
The hs-cTnI test is a cornerstone for diagnosing cardiac events, such as myocardial infarctions, and its integration into POCT devices is nothing short of revolutionary. Traditionally, such tests required centralized labs, delaying crucial decisions in emergency departments and mobile units. With our implementation, these barriers are eliminated:

Exceptional Sensitivity: Ensures reliable detection of cardiac biomarkers.
Rapid Turnaround Times: Facilitates faster clinical decisions during critical moments.
These improvements enable healthcare professionals to act swiftly and confidently, saving lives and enhancing the overall patient experience.

An Open Invitation to the Academic Community
To further validate and expand the potential of this innovation, we’re inviting researchers and academics to join hands with us. Whether your expertise lies in comparative studies, independent evaluations, or clinical publications, we offer an unparalleled opportunity:

Free Access to Our Systems and Tests: Our POCT devices and hs-cTnI tests are available at no cost for qualified academic and clinical research.
Support for High-Impact Research: Collaborate with us to generate groundbreaking findings for publication in leading journals.
This partnership aims to create a robust body of evidence, setting new benchmarks in diagnostics and paving the way for widespread adoption of this life-saving technology.

The Impact of Collaboration
By working together, we can redefine what’s possible in patient care. Academic contributions are crucial to ensuring the credibility and utility of this technology across diverse settings. From urban emergency rooms to remote mobile units, the potential applications are vast.

Through these collaborations, we aim to:

Validate the effectiveness of hs-cTnI in real-world scenarios.
Encourage global standardization of POCT diagnostics.
Inspire innovative approaches to healthcare challenges.
Join Us in Shaping the Future of Healthcare
This is more than a call for collaboration—it’s an opportunity to be part of a transformative journey. If you are passionate about advancing medical science and making a tangible impact on patient care, we want to hear from you. Let’s combine our expertise to create a future where diagnostics are faster, smarter, and more accessible to everyone.

Reach out to us today for more information about this initiative. Together, we can drive innovation and make a lasting difference in healthcare worldwide.

To contact us

Exciting Innovations and Partnerships at MEDICA 2024: Showcasing Our CLIA Test Production and POCT Advancements

At this year’s MEDICA 2024, we’re thrilled to present some groundbreaking updates and innovations, capturing the attention of global audiences and healthcare professionals alike. Held annually, MEDICA is a prime platform for leading industry players, innovators, and visionaries to exhibit cutting-edge advancements in healthcare, diagnostics, and technology. As a proud participant, we’re excited to unveil our newest developments, including our CLIA test production and the region’s first high-sensitivity point-of-care testing (POCT) device for hs-cTnI. Let’s dive into the highlights of our participation and explore what these advancements mean for healthcare providers and patients worldwide.

Expanding CLIA Test Production: Precision and Quality Recognized Internationally
Our CLIA test production has seen a surge of interest, attracting customers from numerous countries and reinforcing our dedication to quality and precision in diagnostics. Our comprehensive CLIA test panels cover a wide range of diagnostic needs, empowering healthcare professionals with reliable tools to make accurate and timely decisions. The attention we’re receiving at MEDICA 2024 underscores the global need for accessible, high-quality diagnostic tests, and we’re committed to meeting this demand through continuous innovation and rigorous quality standards.

By bringing our CLIA production to the global stage, we aim to foster partnerships that expand the accessibility and impact of our products. As we engage with a diverse network of industry professionals, we’re eager to collaborate, exchange knowledge, and explore new markets. Our commitment to quality resonates with healthcare providers looking for reliable and efficient diagnostic solutions, and we’re proud to represent this standard on an international platform.

Join Us at Hall 1, Stand F10: Discover Our Innovations Firsthand
Our booth at Hall 1, Stand F10, offers an immersive experience for visitors interested in our latest diagnostic solutions. Here, attendees can get an up-close look at our advanced CLIA panels and learn about the features and benefits of each test. We’re also offering on-site demonstrations to showcase the ease of use, accuracy, and reliability of our systems.

We understand that seeing our products in action is essential for prospective partners and healthcare providers. By offering demo requests, we invite you to explore our solutions in detail and discuss how our innovations can address specific diagnostic needs. MEDICA is the ideal venue for connecting with industry peers and exploring potential collaborations, and we look forward to meaningful conversations that could lead to groundbreaking partnerships.

A Milestone in Diagnostic Innovation: The First Locally Produced hs-cTnI POCT Device
One of the most exciting highlights of our showcase is our newly developed POCT device, designed specifically for high-sensitivity cardiac troponin I (hs-cTnI) testing. This groundbreaking system is the first of its kind produced locally, representing a significant milestone in accessible and efficient cardiac diagnostics. High-sensitivity hs-cTnI testing plays a crucial role in the early diagnosis and management of cardiac events, providing healthcare professionals with a valuable tool to improve patient outcomes.

Our POCT device enables rapid and reliable hs-cTnI measurements, making it an invaluable asset in emergency care and routine clinical settings. As demand for high-sensitivity diagnostic solutions grows, we’re proud to offer a locally manufactured system that meets rigorous quality standards. This innovation not only enhances diagnostic capabilities for healthcare providers but also supports our mission to elevate patient care through cutting-edge technology.

Driving Global Partnerships and Elevating Patient Care
As we present our innovations at MEDICA 2024, we’re committed to building and strengthening partnerships with healthcare providers, distributors, and institutions worldwide. Our solutions, designed to meet the evolving needs of modern healthcare, offer a unique opportunity for collaboration in advancing diagnostic technology. By connecting with industry leaders and discussing specific diagnostic needs, we aim to create impactful solutions that elevate patient care across borders.

Our participation at MEDICA 2024 is more than an exhibition; it’s a celebration of our dedication to quality, innovation, and global accessibility. We invite you to join us at Hall 1, Stand F10 to discover how our CLIA test production and high-sensitivity POCT device for hs-cTnI testing can enhance diagnostic precision and improve patient outcomes. Together, let’s explore new possibilities for collaboration and innovation in healthcare.